Specify a stock or a cryptocurrency in the search bar to get a summary
Shanghai Bio-heart Biological
2185Shanghai Bio-heart Biological Technology Co., Ltd. operates as an interventional cardiovascular device company in the People's Republic of China. It develops Bioheart, a bioresorbable scaffolds (BRS) system used in percutaneous coronary intervention procedures for the treatment of coronary artery disease; Iberis 2nd, a renal denervation (RDN) product candidate for the treatment of uncontrolled hypertension and resistant hypertension; and drug coated balloon (DCB), a sirolimus drug-eluting balloon catheter designed for instent restenosis. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China. Address: Building 4, Shanghai, China
Analytics
WallStreet Target Price
–P/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures 2185
Dividend Analytics 2185
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History 2185
Stock Valuation 2185
Financials 2185
Results | 2019 | Dynamics |